Novartis Raises Annual Outlook Following Strong Quarterly Performance
Swiss pharmaceutical giant Novartis officially increased its full-year sales and profit guidance on Tuesday, citing robust demand for its flagship cardiovascular and immunology drugs. The Basel-based company reported significant growth in the third quarter, fueled by high-performing assets including the heart failure treatment Entresto and the multiple sclerosis drug Kesimpta. A Strategic Shift in Pharmaceutical…